
Page#1
CONSOLIDATED STATEMENTS OF OPERATIONS
 For the year ended December 31,
2017  2016  2015
(in millions, except per share data)
Net sales $ 2,786.0  $ 2,748.0  $ 2,740.5
Operating costs and expenses: 
Cost of sales 1,770.9  1,758.3  1,786.1
Selling, general and administrative 592.4  597.0  566.5
Asbestos provision —  192.4  —
Transaction related charges 7.8  —  —
Restructuring charges 13.0  —  7.8
Acquisition integration related charges —  —  7.2
 2,384.1  2,547.7  2,367.6
Operating profit 401.9  200.3  372.9
Other income (expense): 
Interest income 2.5  1.9  1.9
Interest expense (36.1)  (36.5)  (37.6)
Miscellaneous expense (0.8)  (1.6)  (0.7)
 (34.4)  (36.2)  (36.4)
Income before income taxes 367.5  164.1  336.5
Provision for income taxes 195.0  40.3  106.5
Net income before allocation to noncontrolling interests 172.5  123.8  230.0
Less: Noncontrolling interest in subsidiaries’ earnings 0.7  1.0  1.1
Net income attributable to common shareholders $ 171.8  $ 122.8  $ 228.9
 
Basic earnings per share $ 2.89  $ 2.10  $ 3.94
Weighted average basic shares outstanding 59.4  58.5  58.1
 
Diluted earnings per share $ 2.84  $ 2.07  $ 3.89
Weighted average diluted shares outstanding 60.4  59.3  58.8
 
See
Notes
to
Consolidated
Financial
Statements
Page 42
Page#2
CONSOLIDATED BALANCE SHEETS
 
  Balance as of December 31,
 2017  2016
(in millions, except shares and per share data)
Assets 
Current assets: 
Cash and cash equivalents  $ 706.2  $ 509.7
Current insurance receivable — asbestos  25.0  18.0
Accounts receivable, net  418.4  396.4
Inventories  349.3  342.5
Current deferred tax assets  —  29.6
Other current assets  19.6  19.5
Total current assets  1,518.5  1,315.7
Property, plant and equipment, net  282.4  278.9
Insurance receivable — asbestos  90.1  125.2
Long-term deferred tax assets  104.2  181.8
Other assets  114.6  95.0
Intangible assets, net  276.8  282.2
Goodwill  1,206.9  1,149.2
Total assets  $ 3,593.5  $ 3,428.0
Liabilities and equity 
Current liabilities: 
Current maturities of long-term debt  $ 249.4  $ —
Accounts payable  247.4  223.2
Current asbestos liability  85.0  71.0
Accrued liabilities  252.1  223.1
U.S. and foreign taxes on income  3.6  3.5
Total current liabilities  837.5  520.8
Long-term debt  494.1  745.3
Accrued pension and postretirement benefits  240.5  249.1
Long-term deferred tax liability  44.9  42.4
Long-term asbestos liability  520.3  624.9
Other liabilities  107.7  99.8
Commitments and contingencies (Note 11)  
Equity: 
Preferred shares, par value $.01; 5,000,000 shares authorized  —  —
Common shares, par value $1.00; 200,000,000 shares authorized; 72,426,139 shares issued; 59,411,636 shares outstanding
(58,964,859 in 2016)  72.4  72.4
Capital surplus  291.7  276.9
Retained earnings  1,813.3  1,719.9
Accumulated other comprehensive loss  (380.1)  (476.1)
Treasury stock; 13,014,503 treasury shares (13,461,280 in 2016)  (452.1)  (459.3)
Total shareholders’ equity  1,345.2  1,133.8
Noncontrolling interest  3.3  11.9
Total equity  1,348.5  1,145.7
Total liabilities and equity  $ 3,593.5  $ 3,428.0
See
Notes
to
Consolidated
Financial
Statements

Page 44
Page#3
CONSOLIDATED STATEMENTS OF CASH FLOWS
 For year ended December 31,
2017  2016  2015
(in millions)
Operating activities: 
Net income attributable to common shareholders $ 171.8  $ 122.8  $ 228.9
Noncontrolling interest in subsidiaries' earnings 0.7  1.0  1.1
Net income before allocations to noncontrolling interests 172.5  123.8  230.0
Asbestos provision —  192.4  —
Gain on deconsolidation of joint venture (1.0)  —  —
Gain on sale of property related to facility consolidation (11.1)  —  —
Restructuring - Non Cash —  —  2.0
Depreciation and amortization 72.7  67.4  67.0
Stock-based compensation expense 21.8  21.7  21.3
Defined benefit plans and postretirement credit (8.5)  (9.1)  (11.6)
Deferred income taxes 102.3  (25.1)  39.7
Cash provided by (used for) operating working capital 54.0  27.0  (16.1)
Defined benefit plans and postretirement contributions (13.2)  (8.8)  (17.9)
Environmental payments, net of reimbursements (6.3)  (11.6)  (18.2)
Payments for asbestos-related fees and costs, net of insurance recoveries (62.5)  (56.0)  (49.9)
Other (3.2)  (3.6)  (17.0)
Total provided by operating activities 317.5  318.1  229.3
 
Investing activities: 
Capital expenditures (49.0)  (51.5)  (39.6)
Proceeds from disposition of capital assets 22.3  0.9  4.4
Impact of deconsolidation of joint ventures (5.2)  —  —
Payments for acquisitions, net of cash acquired (54.8)  —  —
 Total used for investing activities (86.7)  (50.6)  (35.2)
 
Financing activities: 
Dividends paid (78.4)  (77.2)  (76.6)
Reacquisition of shares on open market (25.0)  —  (25.0)
Stock options exercised - net of shares reacquired 25.2  26.4  8.9
Excess tax benefit from stock-based compensation —  —  0.1
Repayment of credit facility —  —  (100.0)
(Repayments) proceeds from issuance of commercial paper - net —  (49.6)  48.8
Debt issuance costs (2.6)  —  —
 Total used for financing activities (80.8)  (100.4)  (143.8)
Effect of exchange rates on cash and cash equivalents 46.5  (20.9)  (33.1)
Increase in cash and cash equivalents 196.5  146.2  17.2
Cash and cash equivalents at beginning of period 509.7  363.5  346.3
Cash and cash equivalents at end of period $ 706.2  $ 509.7  $ 363.5
 
Detail of cash provided by (used for) working capital: 
Accounts receivable $ (10.1)  $ (6.2)  $ (2.4)
Inventories 6.4  24.9  (23.0)
Other current assets 0.8  (2.4)  (3.0)
Accounts payable 17.5  5.5  3.3
Accrued liabilities 30.8  9.6  6.1
U.S. and foreign taxes on income 8.6  (4.4)  2.9
Total $ 54.0  $ 27.0  $ (16.1)
Supplemental disclosure of cash flow information: 
Interest paid $ 36.0  $ 36.8  $ 37.5